​

Bicara Therapeutics Stock (NASDAQ:BCAX)

ForecastFinancialsChart
Bicara Therapeutics by TradingView

Previous Close

$11.98

52W Range

$11.10 - $28.09

50D Avg

$17.15

200D Avg

$20.07

Market Cap

$639.93M

Avg Vol (3M)

$431.00K

Beta

-

Div Yield

-

BCAX Company Profile

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

32

IPO Date

-

Website

BCAX Performance

BCAX Financial Summary

Dec 23Dec 22
Revenue--
Operating Income$-39.89M$-37.66M
Net Income$-51.98M$-37.84M
EBITDA$-51.96M$-37.72M
Basic EPS$-3.37$-2.45
Diluted EPS$-3.37$-2.45

Fiscal year ends in Dec 23 | Currency in USD